NZ593837A - Recombinantly modified plasmin - Google Patents

Recombinantly modified plasmin

Info

Publication number
NZ593837A
NZ593837A NZ593837A NZ59383708A NZ593837A NZ 593837 A NZ593837 A NZ 593837A NZ 593837 A NZ593837 A NZ 593837A NZ 59383708 A NZ59383708 A NZ 59383708A NZ 593837 A NZ593837 A NZ 593837A
Authority
NZ
New Zealand
Prior art keywords
domain
amino acid
polypeptide
terminal
kringle domain
Prior art date
Application number
NZ593837A
Other languages
English (en)
Inventor
Valery Novokhatny
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of NZ593837A publication Critical patent/NZ593837A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ593837A 2007-11-29 2008-11-25 Recombinantly modified plasmin NZ593837A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99114807P 2007-11-29 2007-11-29
PCT/US2008/084645 WO2009073471A1 (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
NZ593837A true NZ593837A (en) 2013-01-25

Family

ID=40379999

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ593837A NZ593837A (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin
NZ585715A NZ585715A (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ585715A NZ585715A (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Country Status (17)

Country Link
US (3) US8101394B2 (enExample)
EP (1) EP2220221B1 (enExample)
JP (1) JP5539896B2 (enExample)
KR (1) KR101529743B1 (enExample)
CN (1) CN101918548B (enExample)
AU (1) AU2008331545B2 (enExample)
BR (1) BRPI0819780B1 (enExample)
CA (1) CA2707266C (enExample)
ES (1) ES2534040T3 (enExample)
HU (1) HUE024916T2 (enExample)
IL (1) IL205936A (enExample)
MX (1) MX2010005947A (enExample)
NZ (2) NZ593837A (enExample)
PL (1) PL2220221T3 (enExample)
PT (1) PT2220221E (enExample)
WO (1) WO2009073471A1 (enExample)
ZA (1) ZA201003730B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5026254B2 (ja) 2004-04-22 2012-09-12 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
UA103771C2 (ru) 2008-06-04 2013-11-25 Грифолз Терапьютикс Инк. Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
HUE025670T2 (en) * 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
JP2016519081A (ja) 2013-03-14 2016-06-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
FR3035120B1 (fr) * 2015-04-15 2020-02-07 Arcadophta Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
CN110114080A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗皮肤纤维化的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CN110366425A (zh) * 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
JP7171572B2 (ja) * 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
CN108210910A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗系统性硬化症的药物及其用途
TWI714862B (zh) 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
US11140020B1 (en) 2018-03-01 2021-10-05 Amazon Technologies, Inc. Availability-enhancing gateways for network traffic in virtualized computing environments
US12226462B2 (en) 2019-01-25 2025-02-18 Council Of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
EP4140498A4 (en) * 2020-05-11 2023-11-01 Talengen International Limited METHOD AND DRUGS FOR TREATING SPINAL MUSCLE ATROPHY
CN118308334B (zh) * 2024-06-06 2024-10-08 深圳市卫光生物制品股份有限公司 一种重组人纤溶酶原及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
AU717435B2 (en) 1996-01-23 2000-03-23 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
WO1999005322A1 (en) 1997-07-22 1999-02-04 Rapigene, Inc. Computer method and system for correlating sequencing data by ms
IL140729A0 (en) 1998-07-14 2002-02-10 Bristol Myers Squibb Co Lysine binding fragments of angiostatin, pharmaceutical compositions containing the same and processes for the preparation thereof
JP4577992B2 (ja) 1998-09-29 2010-11-10 リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー 虚血性卒中の処置用の組成物を調製するための、α２抗プラスミンをインビボで減少する化合物の使用
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
JP2004509609A (ja) 2000-06-02 2004-04-02 ブルー　ヘロン　バイオテクノロジー　インコーポレイテッド 合成二本鎖オリゴヌクレオチドの配列忠実度を改善するための方法
AU2002218890A1 (en) * 2000-12-21 2002-07-01 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
DE10390418D2 (de) 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
JP5026254B2 (ja) * 2004-04-22 2012-09-12 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
BRPI0819780A2 (pt) 2015-08-11
US8101394B2 (en) 2012-01-24
AU2008331545B2 (en) 2014-01-16
CN101918548A (zh) 2010-12-15
BRPI0819780B1 (pt) 2023-01-24
CN101918548B (zh) 2013-10-16
KR101529743B1 (ko) 2015-06-17
US20120093799A1 (en) 2012-04-19
HK1146089A1 (en) 2011-05-13
EP2220221A1 (en) 2010-08-25
IL205936A (en) 2015-04-30
ZA201003730B (en) 2012-11-28
IL205936A0 (en) 2010-11-30
JP2011505140A (ja) 2011-02-24
US8182808B2 (en) 2012-05-22
EP2220221B1 (en) 2014-12-31
AU2008331545A1 (en) 2009-06-11
KR20100102135A (ko) 2010-09-20
JP5539896B2 (ja) 2014-07-02
CA2707266C (en) 2013-12-31
US20120276611A1 (en) 2012-11-01
HUE024916T2 (en) 2016-02-29
WO2009073471A1 (en) 2009-06-11
MX2010005947A (es) 2010-09-10
ES2534040T3 (es) 2015-04-16
PT2220221E (pt) 2015-04-16
CA2707266A1 (en) 2009-06-11
NZ585715A (en) 2011-11-25
US8512980B2 (en) 2013-08-20
US20110003332A1 (en) 2011-01-06
PL2220221T3 (pl) 2015-07-31

Similar Documents

Publication Publication Date Title
NZ593837A (en) Recombinantly modified plasmin
MA28590B1 (fr) Plasmine a modification par recombinaison
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ601094A (en) Modified cry1ca insecticidal cry proteins
NZ588200A (en) Procoagulant peptides
RU2009134725A (ru) Варианты трансглутаминазы с улучшенной специфичностью
ATE400647T1 (de) C-terminale modifikation von polypeptiden
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
Lesner et al. Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery
EP4582442A3 (en) Tnfr2 agonists with improved stability
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
WO2004099254A3 (en) Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells
MX339559B (es) Conjugados de igf-i poli(etilenglicol).
GB0608368D0 (en) Process for making Oligopeptides
TW200604207A (en) A superantigen fusion protein and the use thereof
BRPI0508916A (pt) polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os
WO2008156428A3 (en) Novel peptides and protein and uses thereof
SG170092A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
DK1913020T3 (da) Immunogene konstrukter
DE602004004796D1 (de) Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
MX2025005121A (es) Inhibidores de ccr2 y metodos de uso
TORFF et al. Low molecular weight protease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 NOV 2015 BY DAVIES COLLISON CAVE

Effective date: 20130506

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2016 BY AJ PARK

Effective date: 20151021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2017 BY AJ PARK

Effective date: 20161006

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2018 BY AJ PARK

Effective date: 20170914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2019 BY AJ PARK

Effective date: 20180827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2020 BY AJ PARK

Effective date: 20190828

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2021 BY AJ PARK

Effective date: 20201120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2022 BY AJ PARK

Effective date: 20211012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2023 BY AJ PARK

Effective date: 20221019

LAPS Patent lapsed